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Preponderance of proinﬂammatory signals is a characteristic feature of all acute and resulting long-termmorbidities of the preterm
infant. The proinﬂammatory actions are best characterized for bronchopulmonary dysplasia (BPD) which is the chronic lung
disease of the preterm infant with lifelong restrictions of pulmonary function and severe consequences for psychomotor
development and quality of life. Besides BPD, the immature brain, eye, and gut are also exposed to inﬂammatory injuries
provoked by infection, mechanical ventilation, and oxygen toxicity. Despite the tremendous progress in the understanding of
disease pathologies, therapeutic interventions with proven eﬃciency remain restricted to a few drug therapies with restricted
therapeutic beneﬁt, partially considerable side eﬀects, and missing option of applicability to the inﬂamed brain. The therapeutic
potential of mesenchymal stromal cells (MSCs)—also known as mesenchymal stem cells—has attracted much attention during
the recent years due to their anti-inﬂammatory activities and their secretion of growth and development-promoting factors.
Based on a molecular understanding, this review summarizes the positive actions of exogenous umbilical cord-derived MSCs on
the immature lung and brain and the therapeutic potential of reprogramming resident MSCs. The pathomechanistic
understanding of MSC actions from the animal model is complemented by the promising results from the ﬁrst phase I clinical
trials testing allogenic MSC transplantation from umbilical cord blood. Despite all the enthusiasm towards this new therapeutic
option, the caveats and outstanding issues have to be critically evaluated before a broad introduction of MSC-based therapies.
1. Introduction
Inﬂammatory diseases represent the biggest threat to the pre-
term infant. They aﬀect all organs including the immature
lung, brain, eye, and gastrointestinal tract with extensive
and lifelong consequences for the patient’s health. So far,
eﬃcient therapeutic interventions are restricted to a limited
number of drugs and most pathomechanistic insights are
available for the inﬂammatory damage to the immature lung.
Therefore, this review is focused on the disease pathology of
lung injury and on the therapeutic concepts to protect the
immature lung from inﬂammatory damage. Exogenous mes-
enchymal stromal cells (MSCs) exert many positive eﬀects on
organ development and regeneration [1] and attenuation of
all forms of inﬂammatory processes [2]. Resident MSCs can
play an important role in ﬁbrotic diseases including the
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lung [3]. Therefore, MSC-based therapies have come into
the focus of neonatologists. Here, we summarize the current
evidence on resident MSCs and the therapeutic potential of
exogenous MSCs to reduce the inﬂammatory damage to the
preterm infant.
1.1. Epidemiology of Bronchopulmonary Dysplasia. Broncho-
pulmonary dysplasia is the chronic lung disease of the pre-
term infant which aﬀects more than 60% with a gestational
age< 28 weeks in the US and more than 30% of infants< 30
weeks in Europe [4, 5]. BPD is deﬁned by the clinical criteria
of dependency on oxygen or ventilator support at a corrected
age of 36 weeks of gestation [6] with grading into “mild,”
“moderate,” or “severe” forms [7]. But even infants not fulﬁll-
ing these criteria display persisting limitations in lung func-
tion later in life. Cohort follow-up data substantiate the
inability of lung catch-up growth and the persistence of alter-
ations of pulmonary metabolism into adulthood [8]. The
long lasting limitations probably lead to recurrent pulmonary
sequelae in older age which resemble a COPD-like pheno-
type in the animal model [9]. Beyond the consequences for
exercise capacity and life expectancy, pulmonary sequelae
pose an important threat to the overall quality of life in for-
mer preterm infants with a close association between limita-
tions in lung function and disorders of somatic growth and
psychomotor development [10].
1.2. Distortion of Lung Development by Inﬂammation in the
Preterm Infant. The pathogenesis of BPD is caused by the
distortion of physiologic lung development in the critical
period of the saccular stage. BPD constitutes a multifactorial
disease which is caused by the interaction of a plenty of
pre-, peri-, and postnatal factors. Being small for gestational
age with intrauterine lung growth restrictions caused by
placental insuﬃciency, smoke-induced injury, or diseases
emerging during pregnancy, genetic predisposition and
the immaturity of the lung with its insuﬃciency of anti-
inﬂammatory surfactant production represent important
prenatal conditions. Pre- and postnatal infections, mechani-
cal ventilation, and oxygen supply are the central triggers of
disease pathology with an overwhelming inﬂammatory reac-
tion in the immature lung which induces or further aggra-
vates lung injury [11, 12].
Characteristic features of lung damage initiation are the
overweight of classical proinﬂammatory cytokines including
IL-1β, IL-6, IL-8, and TNF-α and the absence or downregu-
lation of anti-inﬂammatory cytokines including IL-4, IL-10,
and IL-13 and of lung growth factors including growth
factors such as FGFs, VEGFA, and PDGF-A which are
required for further physiologic development of the epithe-
lial, mesenchymal, and endothelial compartments of the lung
[13]. The resulting leaks in the epithelial barrier promote the
inﬂux of inﬂammatory macrophages and neutrophils which
further aggravate lung damage by the release of proinﬂam-
matory cytokines and monocyte chemoattractant proteins
MCP-1, MCP-2, and MCP-3 and macrophage inﬂammatory
proteins MIP-1α, MIP-1β, and TGF-β1 that augment and
sustain the inﬂammatory reaction [14]. The inﬂammatory
overweight turns the signaling pathway equilibrium into a
self-perpetuating disbalance and exaggerated NFκB signaling
which boosts inﬂammation and inﬂammatory cell survival
and aggravates the distortion of the central pathways of lung
development. PDGF receptor α, bone morphogenetic pro-
tein, ﬁbroblast growth factors, PDGFR-α, Wnt/β-catenin,
retinoic acid, VEGFA, and HIF signaling constitute critical
pathways aﬀected [15, 16]. Early alterations observed include
the inactivation of surfactant proteins and the destruction of
organ physiology by cell metaplasia and cell death induction
[17]. The characteristic features described are not restricted
to the epithelial barrier and alveolar development. Their
impact on the mesenchymal and vascular compartment
drives the remodeling of the extracellular matrix and the
disturbance of vascular development [18]. Further vascular
development is disturbed by the inﬂammatory overweight
which suppresses HIF-1α, HIF-2α, and VEGFA activity
[15]. In the mesenchyme, the inﬂammatory response dysre-
gulates the central pathways of EGF receptor activity,
TGF-β1-mediated TTG2, PLOD2, and FGF signaling,
PDGFR-α-dependent VEGFA action, and myoﬁbroblast
and mesenchymal progenitor cell function [12, 16, 19–21].
Not surprisingly, dysregulation of myoﬁbroblasts which orig-
inate from mesenchymal progenitors and are central drivers
of lung development in the saccular stage represents a long-
known hallmark of bronchopulmonary dysplasia [22]. Histo-
pathology reveals a diﬀuse scattering of ACTA-2-positive
myoﬁbroblasts in the mesenchyme, and pathologic function
is reﬂected by disturbed growth factor and extracellular
matrix component secretion and ﬁbroproliferation [23–26].
Of importance, derangement of any of the three compart-
ments of the epithelium, mesenchyme, and endothelium
leads to disruption of lung development [27] and impacts
on the others. The reciprocal interplay between the diﬀerent
pathways and the negative consequences of both inhibition
or overstimulation of the identical pathway as observed
recently for TGF-β1 [28, 29], PDGFR-α, and NFκB add fur-
ther levels of complexity but can explain whymost promising
preclinical therapies failed to prove superiority in the clinical
setting [12, 28–33] (Figure 1).
Taken together, the critical hallmark of BPD is the
dysregulation of the complex signaling network regulating
lung development. Either the activation or inhibition of
any central pathway involved in inﬂammation and/or lung
growth results in severe derangement of pulmonary devel-
opment. Similar pathomechanistic concepts are available
for the inﬂammatory diseases of the cardiovascular system,
immature brain, eye, and gut with overlapping and diver-
gent central signaling pathways which have been reviewed
in detail [34–39].
1.3. Limited Therapeutic Options to Prevent Lung Damage.
Despite the progress in clinical care during the last decades,
the overall incidence of morbidities of the preterm infant
was not reduced due to the steadily increasing survival rates
and the successful therapy of more and more immature
and small infants [40–42]. Based on the pathomechanistic
understanding, far more than 50 diﬀerent approaches to
prevent inﬂammatory injury or to promote organ develop-
ment have been tested in clinical trials [43, 44]. In addition,
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no catch-up growth can be attained later in life [45]. For
BPD, special focus has been drawn to the modulation of
the pulmonary inﬂammatory response. Currently, the ther-
apeutic options are restricted to the anti-inﬂammatory
action of corticosteroids and surfactant and the promotion
of retinoic acid signaling which are centered during the
initial phase of clinical therapy. The eﬃcacy of corticoste-
roids can be explained by the high potency and the impact
on several central pathways of inﬂammation. Due to the
severe side eﬀects on psychomotor development, somatic
growth, and endocrinological homeostasis, this therapeutic
option is actually restricted to rescue therapy in case of
pulmonary failure [46].
Therefore, new therapeutic options based on a molecular
understanding are urgently needed. During the recent years,
MSCs have gained great interest due to their broad anti-
inﬂammatory and development and repair-promoting prop-
erties [47–49]. Therefore, we will ﬁrst summarize physiologic
progenitor cell functions in the preterm infant with special
focus on the lung.
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Figure 1: Pathogenesis of BPD: BPD is the consequence of distortion of alveolar, mesenchymal, and vascular development mainly in the
saccular stage. Central to the disease is the inﬂammatory response which is characterized by a disbalance of cytokines and growth factors,
the inﬂux of inﬂammatory cells, cell death induction, and surfactant inactivation. Distortion of mesenchymal progenitor cell function
represents a key event in disease pathogenesis.
3Stem Cells International
2. Progenitor Cells in Development and Disease
Progenitor cells play a central role in development and dis-
ease. The lung originates from the endoderm and the meso-
derm. While the endoderm gives rise to the epithelium, the
mesoderm develops into the mesenchyme and endothelium.
Lung development is separated into four stages. The pseudo-
glandular stage with the formation of the ﬁrst epithelial buds
in week 5–16 is followed by the canalicular stage where nar-
rowing of the interstitium takes place. At the border of viabil-
ity between 22 and 24 weeks of gestation, saccular stage of
lung development starts which is a very critical and vulnera-
ble period of lung development. Proper lung development
and septation in the saccular stage highly depend on the
interaction between the epithelium, the mesenchyme, and
the endothelium and the proper localization of mesenchymal
progenitors [50]. Currently, we can just speculate on the
impact of further cells like alveolar macrophages and the ner-
vous system. Any noxious insult leads to disturbance of this
highly orchestrated process. Epithelial and endothelial pro-
genitor cells and MSCs play key roles in this critical period,
and any disturbance of their physiologic function leads to
disruption of lung development which was repeatedly dem-
onstrated for MSCs and endothelial progenitor cells in vitro
and in vivo [51–63].
MSCs are the source for several precursor cells in the
immature lung including ﬁbroblasts, lipoﬁbroblasts, and
myoﬁbroblasts. They constitute central regulators of lung
development in the saccular stage, and their multiple actions
during lung development have been reviewed in detail [48,
64, 65]. A special role is ascribed to the production of the
main components of the extracellular matrix including elas-
tin and the secretion of the central drivers of lung develop-
ment including FGF10 [66], Wnt, and PDGF-A [24]. The
MSC population is not uniform but constitutes diﬀerent sub-
sets with cell-speciﬁc function in lung development [67–69].
Paracrine secretion by MSCs constitutes a central mecha-
nism of action with impact on alveolar development and
angiogenesis. Their antiﬁbrotic and antiapoptotic properties
are well accepted for a broad range of diseases [70, 71].
In contrast to terminally diﬀerentiated cells, progenitor
cells from preterm infants are sensitive to noxious stimuli
and more vulnerable than cells from term infants [59, 72]
Oxidative stress and hyperoxic exposure of endothelial pro-
genitor cells are associated with reduced numbers circulating
in the blood probably due to increased susceptibility towards
cell death and accelerated cellular senescence which both can
serve as surrogate markers of endothelial dysfunction and
distorted vascular development. Furthermore, hyperoxic
exposure negatively impacts on paracrine cytokine secretion
including VEGFA and NO synthesis [57–61, 63, 72–74].
Epigenetic gene silencing of SIRT-1 was identiﬁed to be
the critical feature in endothelial progenitors leading to
premature p16 stress-induced senescence. Vice versa, bio-
chemical and molecular SIRT-1 rescue experiments pro-
vided strong evidence for its central role in prevention of
premature senescence of endothelial progenitor cells and
the promotion of vessel formation in vitro and in vivo
[73]. Comparable insights are described for MSCs and
epithelial progenitor cells [75–77]. Taking this into account,
the consequences of reduction of progenitor cells following
lung injury are well explained. They go along with an over-
weight of proinﬂammatory cytokines while protective
growth factors and cytokines are deprived [74]. Genetic var-
iants and antenatal factors further predispose to aggravated
lung damage [11].
Similar observations are described for the immature
brain where neuronal abnormalities and distorted white mat-
ter development resulting in hypomyelination are observed
together with rareﬁcation of progenitor cell populations.
These cells, which are called preoligodendrocytes dominating
the preterm brain, are responsible for myelin sheath forma-
tion but are extremely sensitive towards inﬂammatory and
hyperoxic injury [78].
Therefore, therapeutic targetingof endogenousprogenitor
cells and application of exogenous pluripotent cells represent
two intriguing strategies to prevent or repair inﬂammatory
damage and to promote organ regrowth.
3. Distortion of Resident MSCs in the
Pathogenesis of BPD
A decade ago, MSCs were ﬁrst identiﬁed in the tracheal aspi-
rate of preterm infants and were attributed an important role
in the development of BPD [79]. MSC-speciﬁc characteristic
were conﬁrmed by the adherence to uncoated plastic, the
expression of mesenchymal cell markers including CD73,
CD90, and CD105, the absence of cell surface expression of
CD34, CD45, CD11b, CD14, CD19, CD79α, and HLA-DR,
and the potential of diﬀerentiation into adipocytes, osteo-
blasts, chondrocytes, and myoﬁbroblasts [70, 80]. Overall,
studies conﬁrmed the pulmonary origin by cell surface
marker expression and RNA proﬁling and demonstrated
phenotype alterations not observed in MSCs derived from
other organs and in MSCs from control infants [23]. Recent
data proved the presence of MSCs in the tracheal aspirate
of every preterm infant [81]. Despite the determination of
the pulmonary origin by a lung-speciﬁc pattern, the precise
origin of these cells from the proximal or distal sections in
the lung is not veriﬁed [23]. One possible explanation for
the appearance of these cells in the alveolar lumen is the pro-
motion of migration by the proinﬂammatory cytokine over-
weight induced during lung injury [82]. Three speciﬁc
changes in the pathway pattern were observed in MSCs from
preterm infants later developing BPD. Expression of PDGF
receptor α was reduced which is a characteristic feature of
hypoalveolarization; TGF-β1 secretion and β-catenin signal
transduction were increased which account for myoﬁbroblast
diﬀerentiation, lung ﬁbrosis, and lung cell death induction.
The results from primary MSCs were recapitulated under cell
culture conditions when MSCs were exposed to hyperoxia
and displayed reduced elastin production and diﬀerentiation
into myoﬁbroblasts [19, 83, 84]. MSCs obtained from the tra-
cheal aspirates of preterm infants display a proinﬂammatory
phenotype with higher secretion of proinﬂammatory cyto-
kines including CXCL-1, IL-6, and IL-8 [23]. In a subsequent
study, speciﬁc changes in MSC phenotype were ascribed a
predictive value for the severity of BPD. The MSCs obtained
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from preterm infants later developing severe BPD displayed
more pronounced changes comprising a combined score of
cell phenotype, protein expression, and signal transduction.
The simultaneous increase in proliferation which was
induced by increased NFκB activation was accompanied by
the decrease of cellular α-SMA levels. The in vitro recapit-
ulation of the inﬂammatory milieu conﬁrmed the depen-
dency of phenotype alteration on NFκB. The classical
proinﬂammatory cytokines including IL-1β, IL-6, IL-8, or
TNF-α induced the identical changes as observed in MSCs
from preterm infants with severe BPD, and NFκB target-
ing reverted the proinﬂammatory phenotype [81]. These
proof-of-principle data of phenotype reversibility argue
for a special focus on pulmonary resident MSC character-
istics during the evaluation of any new therapeutic inter-
vention. Vice versa, augmentation of phenotype alteration
or increased cell death induction will aggravate lung
injury. In a recent animal study, the abrogation of TNF-
α-mediated NFκB signaling was associated with increased
apoptosis induction in PDGFR-α-positive mesenchymal
cells mediated by predominant TGFβ1 signaling which
explained the aggravated lung damage during mechanical
ventilation with oxygen-rich gas [25]. These results are a
further example for the complex interplay between the dif-
ferent signaling pathways and the need for a comprehen-
sive evaluation [12, 31].
Taken together, data obtained from human observational
studies and in vitro investigations clearly demonstrate that
phenotype alterations of resident lung MSCs are associated
with the development of BPD. We speculate that reprogram-
ming of resident pulmonary MSCs represents a promising
new therapeutic option. Next, we will focus on the therapeu-
tic potential of exogenous MSCs.
4. Positive Effects of Exogenous MSCs on the
Diseased Lung
During the recent years, a tremendous eﬀort has been under-
taken to investigate and optimize stem cell-based therapies in
diﬀerent acute and chronic diseases. Preclinical results
mainly from the rodent model [74, 85–91] but also ﬁrst clin-
ical studies hint to a tremendous potential of stem cell-based
therapies to alleviate or cure diseases of the preterm infant
[92–94]. MSCs represent the most extensively studied cell
population for therapeutic use, and MSCs from diﬀerent tis-
sues have been tested to prevent the damage to the immature
lung or to alleviate the severity of lung damage. Despite the
progress in animal studies, the precise molecular mecha-
nisms how these therapies alleviate lung damage remain
to be determined. The following chapter summarizes the
preclinical evidence available to prevent or treat damage
to the preterm lung by exogenous MSC application [71].
The main focus is drawn to give a comprehensive over-
view of the pathomechanistic understanding based on the
studies in the diﬀerent rodent models. Due to the limita-
tions in space, no critical evaluation of diﬀerences in study
quality and no separated consideration of MSCs from the
umbilical cord blood or bone marrow are presented. We
acknowledge the preclinical promising evidence of other
cell-based therapies with cell products from the amniotic
ﬂuid, Wharton’s Jelly, placenta and fetal membranes, and
the work with endothelial progenitors and refer to actual
comprehensive reviews [95, 96].
MSCs from the umbilical cord or bone marrow have
attracted the greatest interest due to the easy accessibility,
their multipotency, immune privilege, and low immuno-
genic potential, and their positive impact on the epithelial,
mesenchymal, and vascular compartment of the lung. The
ﬁrst pioneering studies performed in rodents demonstrated
beneﬁcial eﬀects of the application of bone marrow-derived
exogenous MSCs on survival, lung morphology including
alveolar septation, vessel density, and the functional parame-
ters of pulmonary arterial pressure and lung function testing
[74, 89, 91, 97, 98]. Beneﬁcial eﬀects were uniformly con-
ﬁrmed in all subsequent studies using the identical approach
in the rodent model [85, 87, 88, 99–103]. Identiﬁed functions
cover all property characteristics for MSC-based therapies
and comprise plenty of lung protective mechanisms includ-
ing lung development promoting anti-inﬂammatory, antiox-
idative, and antiapoptotic actions. These results increased
survival, the promotion of alveolar and vascular growth, the
proper composition of the extracellular matrix, and the inhi-
bition of lung ﬁbrosis [85, 90, 93, 99, 104, 105]. The identical
positive eﬀects were demonstrated for the important and fre-
quent clinical situations of perinatal inﬂammatory exposure
or intrauterine growth restriction followed by hyperoxic
injury. Both settings revealed identical beneﬁcial eﬀects of
MSC transplantation for all areas of interest [106, 107]. The
positive eﬀects of exogenous MSCs on lung architecture are
not of transient nature, but follow-up examinations con-
ﬁrmed the long-term beneﬁcial eﬀects on inﬂammatory
properties in the lung and lung morphometry. Thereby,
the persistent long-term positive eﬀects of both exogenous
MSCs despite low engraftment and rapid fade away of the
donor cells and of their conditioned media (100, 105) sug-
gest that the paracrine protective eﬀects induced by the
transplanted stem cells might initially play a pivotal role
in tissue repair (93, 100, 105). As the donor cells fade
away, the intact host tissue that is protected by stem cell
transplantation might be responsible for the sustained
upregulation of various paracrine factors, thus the persis-
tent beneﬁcial eﬀects.
On a molecular level, MSC therapy leads to a reduction of
pulmonary inﬂammatory response to hyperoxic injury.
MSCs have a positive impact on all characteristic proinﬂam-
matory features. The classical proinﬂammatory cytokine
levels are reduced including IL-1β, IL-6, MIP-1α, and TNF-
α, and the central growth factors and anti-inﬂammatory
cytokines including VEGFA, HGF, and IL-10 are upregu-
lated while TGF-β1 levels are decreased. This restoration of
cytokine balance leads to an attenuated inﬂux of inﬂamma-
tory macrophages and neutrophils into the lung. Further-
more, the reduced pulmonary inﬂammatory response was
accompanied by an increase in VEGFA and CTGF signaling
and improved lung morphology [106]. MSC transplantation
leads to the attenuation of indicators of oxidative stress,
reduction of inhibitors of metalloproteinases, adhesion mol-
ecules like RANTES, L-selectin, and soluble intercellular
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adhesion molecule-1 [104], and the preservation of mTOR
and tCRABP1 signaling which are key regulators of cell pro-
liferation and retinoic acid pathway, respectively [107].
The last but not the least, application of exogenous MSCs
preserves the production of surfactant proteins after
hyperoxic injury [91]. The beneﬁcial impact on lung
growth with improvements in alveolar and vascular devel-
opment is accompanied by reduced cell death induction.
The reduced expression of genes involved in cell death
including the gatekeeper of apoptosis p53 is accompanied
by a diminished activation of eﬀector caspases, fewer
number of apoptotic cells, and attenuated interstitial lung
ﬁbrosis with a decrease in proﬁbrotic genes like CTGF,
TIMP-1, collagen-1α, α-SMA, and TGF-β1 [85, 86, 89,
102, 108] (Figure 2).
Besides the direct anti-inﬂammatory action, data from
the bone marrow-derived MSC transplantation argue for
a lung self-renewal eﬀect as their application into the
lung leads to an increase of bronchoalveolar stem cells.
[101]. Experiments in the rodent provide evidence that
MSC application contributed to the uprise of decreased
growth factors like VEGFA and HGF by paracrine secre-
tion [104, 109]. On a molecular level, RNA interference
against VEGFA in exogenous MSCs before application
to the injured lung prevented the described increase in
VEGFA and concomitantly had a negative impact on all
features of hyperoxic lung injury including inﬂux of mac-
rophages, proinﬂammatory cytokine release, cell death
induction, and distortion of alveolar and vascular growth
[109] (Figure 2).
The beneﬁcial eﬀects of MSCs are dose dependent, and
the transplantation of low numbers of MSCs restricts the
positive eﬀects to some of the described MSC features.
Diﬀerent routes of administration have been compared,
and intratracheal and intravenous application showed
therapeutic eﬃcacy which is in line with the data that
stem cells from nonlung tissue can contribute to the atten-
uation of lung injury [90]. Evidence suggests that the
probable dominant mode of action of MSCs is by para-
crine eﬀects. The results from animal trials on the other
hand suggest also a direct cellular activity which cannot
be substituted by cell-free supernatants or exosome prepa-
rations and includes mitochondrial transfer. The latter
might be of high importance as pathogenesis of BPD is also
ascribed to mitochondrial dysfunction [74, 100, 110, 111].
So far, detailed data on the diﬀerences between MSC
cell-based therapies and application of cell-free extracts,
isolated microparticles, or exosomes are missing despite
the high enthusiasm about these advanced technologies
[105]. Concerns have to be raised with respect to thera-
peutic equivalence as in the rat hyperoxic model, intratra-
cheal application was superior to the intravenous route.
Whether this discrepancy can be ascribed to the dose-
response relationship remains unclear. The studies available
suggest that the therapeutic beneﬁt of MSC cell therapy
is higher for alveolar morphology and lung ﬁbrosis
scores which was reproduced by two independent groups
[100, 103, 108]. Ex vivo preconditioning might represent
a possibility to improve therapeutic eﬃciency of cell-free
extracts [88].
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Figure 2: The therapeutic potential of allogenic mesenchymal stromal cells: allogenic MSC transplantation for prevention or therapy of lung
injury has been studied in detail in the rodent model. The scheme summarizes all beneﬁcial eﬀects following allogenic MSC therapy with
separation of the positive eﬀects on inﬂammation and organ development.
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5. Further Areas of Research with Exogenous
MSC Application
Besides the therapeutic potential of MSCs to prevent or
reduce the severity of pulmonary sequelae, all other disease
entities of the preterm infant with inﬂammatory properties
and loss of cell function are potential targets for cell-based
therapies. The current status of MSC-based therapies is sum-
marized in Figure 3.
The central nervous system is the second organ most
aﬀected by injury to the preterm infant and therefore has
attracted special attention during recent years. Data obtained
in preclinical and clinical studies to date suggest a high ther-
apeutic potential of MS-based therapies for cardiovascular
diseases, gastrointestinal complications, and retinopathy of
prematurity [112–114] which represent further disease enti-
ties with dominating inﬂammatory properties (reviewed in
[95]). So far, most preclinical studies in the rodent model
were performed for brain pathologies of the term newborn
infant including hypoxic brain injury following perinatal
asphyxia and neonatal stroke. Actual studies also evaluated
the therapeutic potential of MSC therapy in periventricular
leukomalacia and intraventricular hemorrhage [115–128].
For intraventricular hemorrhage, the contributions of
inﬂammatory reaction to disease pathologies are well estab-
lished and include brain damage by cell death induction of
neurons and distortion of further myelination and gliosis
[34, 129]. In analogy to the inﬂammatory damage to the
immature lung, the selective therapeutic blockade of one
inﬂammatory pathway leads only to a modest or no improve-
ment in brain morphology. In addition, central regulatory
pathways of organ damage diﬀer partly from that involved
in lung injury as observed for TGF-β1 signaling but can be
common regulators as for macrophage attraction and proin-
ﬂammatory cytokine production [129–135]. Therefore, the
broader approach of targeting several inﬂammatory actions
as achieved with MSC treatment is reasonable and proven
eﬃcient in the rodent model with respect to all relevant brain
pathologies including astrogliosis, myelination, cell death
induction, and prevention of posthemorrhagic hydrocepha-
lus. Morphologic beneﬁts were accompanied by a strong
reduction in classical proinﬂammatory cytokines like IL-1α,
IL-1β, IL-6, and TNF-α and improved performance in
behavioral function tests [34, 122]. Brain-derived neuro-
trophic factor (BDNF) seems to play a pivotal role in the pre-
vention of brain injury, as siRNA knockdown before MSC
transplantation abrogated the beneﬁcial eﬀects of MSC trans-
plantation on all morphologic and functional features in the
rat model of intraventricular hemorrhage including inﬂam-
matory reaction, cell death induction, myelination, astroglio-
sis, attenuation of posthemorrhagic hydrocephalus, and
behavioral test performance [34, 122, 136]. Comparable
results were obtained for MSC therapy with cells overex-
pressing BDNF after hypoxic-ischemic insult and underline
the dominant function of BDNF in the brain [137].
The intraventricular route tested in some animal models
[120, 122] is restricted by the potential deleterious eﬀects of
direct intracerebral injection. Intravenous [138], intracardial
[139], and intranasal [119, 125, 127] administration of MSCs
proved therapeutic eﬃciency, and intravenous application
revealed similar eﬃcacy with respect to brain morphology
parameters and functional read-outs compared to the intra-
ventricular route despite a reduced MSC deposition in the
brain tissue [123]. Adjustment of MSC numbers transplanted
was a prerogative for comparable eﬃcacy, and scientiﬁc data
suggest a minimal eﬀective dose for MSC transplantation. In
contrast to the lung, repeated application proved superiority
with positive eﬀects on the inﬂammatory response and neu-
ronal apoptosis, brain morphometry, and reactive astroglio-
sis [118, 119, 128, 140]. Optimal timing is much more
critical as the inﬂammatory reaction following IVH is
restricted to a short peak which restricts the therapeutic win-
dow [127, 136]. The limited time period can be explained by
the cessation of MSC attraction to the site of injury after the
short peak of cytokine secretion. In the model of periventri-
cular white matter injury, bone marrow MSCs were attracted
from the site of injection to the site of inﬂammatory
injury. The lacking diﬀerentiation of these cells into neu-
ronal cells suggests a paracrine neuroprotective eﬀect
[120, 124, 127, 141]. As the central nervous system repre-
sents a special compartment with reduced immunologic
properties, special concerns have to be drawn to the persis-
tent prevalence of MSCs in the brain which has not been
studied for the IVH and periventricular white matter injury
models so far. In the studies on hypoxic injury, emergence
of neoplasia was not detected. [125].
Of importance, the results from the hypoxic ischemic
brain injury model suggest that combination of MSC applica-
tion with the currently practiced evidence-based therapy of
therapeutic hypothermia proved superiority compared to
each single strategy. The combined approach was the most
eﬃcient with respect to the reduction of proinﬂammatory
cytokines, apoptotic cells in the brain, microgliosis, astrocy-
tosis, and functional limitations [121]. These results encour-
age the pursuit of combinatorial treatment regimens not only
in the brain but also in the lung together with therapies with
proven eﬃcacy to prevent BPD-like surfactant application.
6. MSC Application in Phase I Clinical Trials
A pioneering phase I study to reduce the severity of BPD per-
formed in South Korea was published 3 years ago which
demonstrated superiority of exogenous MSC application
derived from the umbilical cord blood of healthy newborn
infants [94]. MSCs were applied once between days 5 and
14 of life to n = 9 infants at high risk for BPD of 24 to 26
weeks of gestation requiring mechanical ventilation and
showing deteriorating respiratory function. A signiﬁcant
reduction in BPD severity was observed compared to a con-
trol cohort of untreated infants. MSCs were applied in two
slightly diﬀerent dosages which do not allow any conclusion
about the optimal number of cells. As expected from the ani-
mal experiments, the extent of proinﬂammatory cytokine
response was reduced in the tracheal aspirates following
MSC administration and no acute toxicities or side eﬀects
were observed until the age of approximately 3 months.
The long-term follow-up of safety and eﬃciency is still pend-
ing. Recently, the follow-up at the age of 2 years was
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published. Despite all the limitations due to the study size,
promising data were added for home oxygen, rehospitaliza-
tion due to pulmonary sequelae, somatic growth, and motor
development [92].
In addition to the trials to prevent BPD, two studies on
hypoxic ischemic brain encephalopathy and severe intraven-
tricular hemorrhage were conducted during the recent years.
The open-labeled study on hypoxic brain injury used autolo-
gous umbilical cord blood cells plus therapeutic hypothermia
[142]. The evaluation of acute toxicities revealed no acute
adverse reactions including cardiovascular compromise or
nosocomial infection. The standardized follow-up at the age
of 12 months revealed superiority of cell therapy with a com-
bined reduction of neurodevelopmental compromise or
death from 59% to 28%. The deﬁnite interpretation of the
data is hampered by the incomplete follow-up. The enroll-
ment within the IVH study is completed, and no acute
toxicities were preliminarily described, but psychomotor
follow-up is still awaiting publication [143].
The death of one infant in the MSC group due to sepsis at
the age of 4 months in the BPD trial and two additional
deaths due to viral infections in the intervention group
in the MSC trial for hypoxic ischemic brain injury must be
mentioned which occurred in severely handicapped infants
[92, 142]. Due to the time period of several months between
cell-based therapy and the onset of infection, a direct causal
relationship is not probable, but infectious complications
should be carefully monitored in the ongoing (follow-up)
studies [144].
Taken together, the ﬁrst phase I MSC trials render prom-
ising results and advocate the further evaluation of MSC
therapy to reduce the deleterious eﬀects of inﬂammatory
injury to the preterm infant. As these lesions are not
restricted to the lung and brain, actual and future studies
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Pulmonary hypertension (PHT)
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ROP
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Evidence from preclinical and phaseI clinical studies 
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Postulated therapeutic potential of MSC-based therapies without preclinical or clinical evidence
Figure 3: Therapeutic potential of MSC therapy in the preterm and newborn infant: beyond prevention or therapy of lung injury following
preterm birth, MSC-based therapies have a therapeutic potential for all inﬂammatory diseases of the preterm and newborn infant. The scheme
summarizes the current status of MSC-based therapies for the lung, brain, gut, eye, and cardiopulmonary system. The scientiﬁc knowledge is
separated into evidence from phase I clinical trials and preclinical studies mainly in rodents and a presumed therapeutic potential.
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should carefully consider all other organs prone to inﬂamma-
tory injury including the cardiovascular system, the gut, and
the eye (Figure 3).
7. Current Therapeutic Obstacles to
MSC Therapy
Despite the tremendous progress in the pathomechanistic
understanding of the therapeutic potential of MSC therapy
from the rodent models to overcome the deleterious eﬀects
of inﬂammatory diseases in the preterm infant, the broad
application of exogenous MSCs to the preterm infant is still
hampered by a huge gap of knowledge. Central obstacles
include the following: (1) the selection of the most eﬀective
cell preparation fulﬁlling quality criteria which yet have to
be deﬁned, (2) the optimal number, time point, and route
of MSC cell administration, and (3) the need for validation
of clinical criteria to predict the infant at risk beneﬁting from
such a therapy. At present, MSCs represent the most promis-
ing candidates for prevention or treatment of BPD and other
inﬂammatory diseases of the preterm infant as MSCs proved
therapeutic eﬃcacy in several animal models mimicking
BPD, intraventricular hemorrhage, or periventricular white
matter injury. In contrast, data on alveolar and endothelial
progenitor cells and on epithelial cells from the amniotic
ﬂuid [145] display considerable gaps in knowledge with
respect to therapeutic eﬃciency and cell product preparation.
Furthermore, experience with the therapeutic potential of
endothelial progenitors is restricted to rodent models and
might be limited to paracrine eﬀects which can solely rescue
vascular outgrowth while epithelial progenitors from the
amniotic cavity mainly limit inﬂammatory processes. MSCs
from umbilical cord blood from donor newborn infants can
be prepared in suﬃcient quantity but harbor the risks of allo-
genic transplantation although the ﬁrst phase I clinical trials
did not show any short-term side eﬀects [94, 142, 146]. Isola-
tion and expansion techniques are still not standardized har-
boring the risk of variable quality of MSC cell preparations.
Currently, MSC diﬀerentiation during expansion and related
loss of function cannot be monitored by quality control
assays, but expansion in cell culture using xeno-free media
represents a promising research direction [147]. Further-
more, expansion of autologous MSCs should be taken into
the conceptual consideration to overcome the risks and ethi-
cal concerns of allogenic transplantation. The application of
cell-free supernatants represents an alternative approach to
bypass the concerns of allogenic transplantation, but results
from animal experiments suggest that the therapeutic eﬃ-
ciency of MSC therapy is mediated by paracrine eﬀects and
direct cell interaction at least for BPD [93, 105, 148]. There-
fore, MSCs from the umbilical cord blood constitute cur-
rently the therapeutic option closest to clinical use. The
beneﬁcial eﬀects of comparatively high dosages of MSCs in
the rodent model were reproduced in the single phase I clin-
ical trial in infants, but the optimal time point for administra-
tion and MSC number remains to be determined. Data from
the rodent model suggest that the early preventive applica-
tion is superior to the late administration to the injured lung
and brain. For BPD, actual data do not allow the conclusion
that repeated applications are superior to a single dose
while repetitive treatments showed superiority for preven-
tion of the deleterious eﬀects of intraventricular hemorrhage
[74, 104, 108, 118, 119, 123, 125, 127, 128, 140]. As the major-
ity of preterm infants can be stabilized on noninvasive venti-
lator support with or without the additional application of
surfactant during spontaneous breathing and are generally
ventilated much shorter than during the past decades, the
intratracheal route of application is restricted to the most
severely aﬀected preterms. Uniform distribution of MSCs as
ensured for surfactant must be established for any noninva-
sive application procedure. The intravenous application con-
stitutes an appealing alternative in the preterm infant but has
not been studied at all and requires thorough preclinical eval-
uation. Whether the superiority of intratracheal application
of MSCs in the rat model can be attributed to discrepancies
in cell numbers delivered to the site of injury remains to be
determined. The observed diﬀerences in therapeutic eﬃcacy
raise concerns about the therapeutic eﬃciency of the intrave-
nous route [108]. Finally, the inﬂammatory injuries to the
preterm infant result from complex pathophysiologies and
resulting disorders currently cannot be predicted based on
clinical parameters at birth. While risk calculators can nar-
row the population at risk, reliable biomarkers are urgently
needed for reliable patient selection and monitoring of ther-
apeutic eﬃciency. The trustworthy selection of infants at
high risk is a prerogative for any further therapeutic evalua-
tion of allogenic MSCs in larger scale controlled studies of
MSC-based therapies at this stage.
Experimental data on exogenous and resident pulmonary
MSCs suggest that both the application of exogenous physio-
logic cell preparation and the reprogramming of resident
pulmonary MSCs represent highly promising therapeutic
interventions. While the therapeutic potential of reprogram-
ming resident pulmonary MSCs is still at the very beginning
and limited to in vitro investigations, the application of exog-
enous MSCs requires thorough studies addressing the con-
cerns raised above. One often ignored argument against
exogenous MSC preparation is that these cells do not display
all properties inherent to resident pulmonary MSCs and that
safety issues must be taken into account concerning poten-
tial long-term side eﬀects which require decades of research
before deﬁnitive answers can be given for the preterm situa-
tion. It is clearly established that exogenous MSCs do not
possess the capability to produce lung growth factors and
cytokines and lung-speciﬁc proteins including that of the
extracellular matrix and do not have the characteristic pro-
ﬁle of upregulated transcriptions factors speciﬁc for the lung
[23, 149, 150]. Special consideration has to be given to the
inherent immune system as MSCs can impact on immune
cell proliferation and function including dendritic cells, NK
cells, and T and B lymphocytes [70, 71, 151]. Therefore,
the reports on unexplained deaths due to severe infections
as well as the potential risk of malignant transformation in
the immune compromised preterm infant have to be evalu-
ated carefully and with respect to the long-term outcome
although current data suggest that MSCs in contrast to
embryonic stem cells do not display, that is, teratogenic
potential even during compromise of the immune system
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[92, 142, 144, 152]. Finally, it is currently impossible to pre-
dict whether genomic instability during MSC expansion is
responsible for the altered behavior in vitro during passaging
and whether cell propagation gives rise to subpopulations
with heterogeneous properties. To overcome these obstacles,
MSC-derived supernatants or exosomes represent intriguing
alternatives with promising results in ﬁrst animal trials [153]
but as long as it cannot be excluded that cellular MSC com-
ponents like mitochondria contribute to the protection from
inﬂammatory injury—especially since MSC-derived exo-
somes showed mitochondria-like aerobic metabolism in
one study [154]—a lot of preclinical research activity is
needed before safe introduction into clinical trials.
Taken together, MSC-based therapies represent a highly
promising research ﬁeld to ameliorate or overcome the dele-
terious eﬀects of overwhelming inﬂammation in the preterm
infant. Despite the tremendous progress in pathomechanistic
understanding obtained from animal trials during the recent
years and the ﬁrst promising phase I clinical trials, a lot of
research eﬀort is needed to bring the optimized MSC product
into the upcoming clinical trials. As we have learned from the
multicenter studies from the past, the look at the long-term
aspects is of central importance for the overall and sustained
success of stem cell-based therapies in the preterm infant.
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